Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPOR | P19235 | 8/20 | 0.35 |
| ▸ | FAP | Q12884 | 3/20 | 0.34 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.33 |
| ▸ | FURIN | P09958 | 2/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27231233 | 0.88 | FAP (0.35) | EPORFAPMAP1LC3BSIRT2SIRT1 | |
| SCHEMBL30874648 | 0.88 | TLR2 (0.41) | SIRT2SIRT1SIRT5 | |
| SCHEMBL27213475 | 0.85 | SIRT2 (0.36) | SIRT2SIRT1FURINSIRT5 | |
| SCHEMBL27148471 | 0.83 | FURIN (0.34) | FAPMAP1LC3BSIRT2SIRT1FURIN | |
| SCHEMBL19681567 | 0.82 | FURIN (0.39) | FAPMAP1LC3BFURINSIRT5 | |
| SCHEMBL30992313 | 0.81 | CASP3 (0.40) | SIRT2SIRT1SIRT5 | |
| SCHEMBL21738589 | 0.81 | CASP3 (0.40) | SIRT2SIRT1SIRT5 | |
| SCHEMBL21738670 | 0.81 | CASP3 (0.40) | SIRT2SIRT1SIRT5 | |
| SCHEMBL29077855 | 0.81 | FURIN (0.36) | FAPMAP1LC3BSIRT2SIRT1FURIN | |
| SCHEMBL23880545 | 0.80 | TLR2 (0.39) | FAPMAP1LC3BFURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4548937-A1 | ANTIBODY-DRUG COMPLEX | Eisai R&D Management Co., Ltd. (JP) | 2025-05-07 | — | — | EP | disclosed |
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | ANTXR2, FCGR1A, HAX1 | EPOR 992/4885FAP 4440/4885MAP1LC3B 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.